13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE Filed 2026-01-27 Event 2026-01-23 SEC 0001231919-26-000093 →

Frazier Life Sciences IX, L.P. Mirum Pharmaceuticals, Inc. MIRM

Stake: 6.80% Shares: 4,108,404 CUSIP: 604749101 Class: Common Stock, par value $0.0001 per share

Item 4 — Purpose of Transaction

Item 4 is hereby amended and restated in its entirety to read as follows: Each of FLS IX, FLS X, FLSPF, FLS XI and FLS XII acquired the FLS IX Shares, the FLS X Shares, the FLSPF Shares, the FLS XI Shares and the FLS XII Shares, as the case may be, for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, FLS IX, FLS X, FLSPF, FLS XI and FLS XII and the other Reporting Persons may dispose of or acquire additional shares of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or (j) Any action similar to any of those enumerated above.

Cross-References

Insider Activity (last 365d)
5 transactions
0 buys · 1 sales · 4 awards/exercises
Issuer Cluster
8 13D/G filings on this issuer
7 other filings besides this one
Filer Track Record
6 filings by this filer
5 other filings in the data moat
Short Interest · settle 2026-07-15
DTC 10.59
7,272,892 shares short · -2.8% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers
1 holder · $16.35M
Point72 Asset Mgmt

Post-Filing Returns · since 2026-01-23 on MIRM

+1 day
0.0%
+5 days
0.0%
+30 days
0.0%
+60 days
0.0%
+90 days
0.0%
+180 days
-10.8%

Anchor price 128.31 on closest trading day on/after 2026-01-23. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Form 4 Insider Transactions · last 365d

DateInsiderRoleTypeSharesPriceValue
2026-06-01 Peetz Christopher director, officer Option exercise 30,000 $2.94 $88K
2026-06-01 Ramasastry Saira director Sale 3,977 $100.00 $398K
2026-05-29 Walbert Timothy P director Option exercise 3,977
2026-05-29 Cardon Lon director Option exercise 3,977
2026-05-29 Ramasastry Saira director Option exercise 3,977

Other 13D/G Filings on Mirum Pharmaceuticals, Inc.

FiledFormFilerStakeShares
2023-09-05 SC Frazier Life Sciences IX, L.P. view →
2022-08-18 SC Novo Holdings A/S view →
2020-12-22 SC RiverVest Venture Fund IV, L.P. view →
2020-12-18 SC Frazier Life Sciences IX, L.P. view →
2020-12-18 SC Novo Holdings A/S view →
2020-04-29 SC Frazier Life Sciences IX, L.P. view →
2020-01-17 SC Novo Holdings A/S view →

Other Filings by Frazier Life Sciences IX, L.P.

FiledFormIssuerStakeShares
2023-09-05 SC Mirum Pharmaceuticals, Inc. MIRM view →
2022-09-26 SC Phathom Pharmaceuticals, Inc. PHAT view →
2021-01-27 SC Passage BIO, Inc. PASG view →
2020-12-18 SC Mirum Pharmaceuticals, Inc. MIRM view →
2020-04-29 SC Mirum Pharmaceuticals, Inc. MIRM view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →